

**The Correlation between Genetic Polymorphism
of P2Y12, PON1, CYP2C19, CES-1 and PEAR-1 and
Clinical Response to Dual Antiplatelet Treatment
in Egyptian Patients with Acute Coronary
Syndrome**

Thesis submitted for fulfillment of requirements for

Ph.D Degree in Pharmaceutical Science

(Clinical Pharmacy)

By

Shaimaa Fathy Mohamed Khalil

B. Pharm Sci. 2004

M.Sc. Pharm Sci (Clinical Pharmacy), 2011

Teaching Assistant of Clinical Pharmacy and Pharmacy Practice.

Faculty of Pharmacy, Misr International University.

Under Supervision of

Prof. Dr. Nagwa Ali Sabri Prof. Dr. Mohamed A. Saleh

Professor of Clinical Pharmacy

*Faculty of Pharmacy, Ain Shams
University*

Professor of Cardiology

Faculty of Medicine, Ain Shams University

Prof. Dr. Mona Schaalán

Professor of Biochemistry

*Faculty of Pharmacy, Misr International
University (MIU)*

Dr. Lamia Elwakeel

*Associate Professor of Clinical Pharmacy
Faculty of Pharmacy, Ain Shams University*

*Faculty of Pharmacy
Ain Shams University*

2018

ACKNOWLEDGEMENT

First and foremost, praises and thanks to **God**, the Almighty, for his blessings throughout my research work to complete the research successfully.

It has been an honor to have *Prof. Dr. Nagwa Ali Sabri* , Professor and Head of Clinical Pharmacy and Pharmacy Practice department, Faculty of Pharmacy, ASU, as my supervisor. I would also like to thank her for her active supervision, constructive criticism, useful comments, supportive guidance throughout the work and efforts in revising the thesis. She helped me a lot in finalizing all the required work, and facilitating the whole process and solving any problem easily.

My deepest thanks to *Dr. Lamiaa Elwakeel* , Associate Professor of Clinical Pharmacy, Faculty of Pharmacy, ASU, for her continuous support, sincere efforts to facilitate the difficulties during this work, and her valuable guidance, and constructive criticism in revising the thesis.

I would like to extend my cordial appreciation to *Prof. Dr. Mohamed Ayman Saleh*, Professor of Cardiology, Faculty of Medicine, ASC, for his generous help, his assistance in selection of patients for the study, and facilitating collection of required samples from his cardiology unit, ASU, as well as his valuable, scientific contribution in this research.

Words cannot express my deep gratitude and sincere appreciation to *Prof. Dr. Mona Schalaan*, Professor and Head of Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, MIU, for her endless support. I do very much appreciate her role in providing me the research channel opportunity to complete my practical work in the Center for Pharmacogenomics in Florida University. Without her communication with *Dr Julie Johnson*, Dean of College of Pharmacy, Florida University and *Dr Larisa Cavallari*, Head of Department of

Pharmacotherapy and Translational Research, Center for Pharmacogenomics, it would have been impossible to pursue and reach where I am now. Dr. Mona is my role model and will always be my dear mentor and sincere friend. I do love her on both personal and professional levels.

I would like to express my gratitude to *Prof. Larisa Cavallari*, Professor and Head of Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, University of Florida, for her continuous advice, professional guidance, valuable suggestions, and generous help.

I would also like to express my deepest gratitude to *Dr. Mohamed Shahin*, Associate Professor, at the Center for Pharmacogenomics, College of Pharmacy, University of Florida, for providing a comfortable environment in the lab, and supporting me in every step. Moreover, I would like to express my gratitude for his continuous advice, valuable suggestions, input, and guidance in publishing the manuscript. I am also very much obliged to the kindness and great help of *Lynda Stauffer* at the University of Florida, Center for Pharmacogenomics, Florida, for her laboratory assistance.

Furthermore, I would like to convey my special thanks to my colleagues at National Heart Institute, Ain Shams Specialized Hospital, and Al-Demerdash Hospital, Cairo, Egypt, for their cooperation in samples collection, as well as kind receptiveness.

I am thankful to **Misr International University (MIU)** for the financial support they provided to finalize my mission in the best way. It offered me a great opportunity to do my practical work in Center of Pharmacogenomics, University of Florida, where I learnt a lot. I would like to extend my gratitude to MIU professors and colleagues for their vital assistance and motivation.

Last, but not least, my deep thanks and gratitude to my parents, for giving me life in the first place, educating me, their unconditional love, psychological support and encouragement to pursue my scientific interests. I also would like to convey special appreciation and gratitude to my husband for his encouragement and support and moreover his kindness, tolerance and patience in accompanying me during my journey to Florida, leaving all his responsibilities and work for only the sake of taking care of me and my son. Finally, I would like to thank all my friends and colleagues for their continuous support and believing in me to finalize this difficult mission and to reach my dream as PhD holder and faculty member in the Clinical Pharmacy Department at MIU.

Shaimaa Fathy Khalil

List of Abbreviations

Abbreviation	Stands for
<i>ABCB1</i>	Adenosine Triphosphate (ATP)-Binding Cassette, Sub-Family B
AC	Adenylate Cyclase
ACC	American College of Cardiology
ACE	Angiotensin Converting Enzyme
ACS	Acute Coronary Syndrome
ACTIVE	Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
ADP	Adenosine Diphosphate
AHA	American Heart Association
AMI	Acute Myocardial Infarction
APCs	Antigen-Presenting Cells
APS	Adenosine 5' Phosphosulfate
ARBs	Angiotensin Receptor Blockers
AST	Aspartate Aminotransferase
ATP	Adenosine Triphosphate
BAFF	B-cell Activating Factor
BCHE	Butyrylcholinesterase
BMI	Body Mass Index
BNP	B-Natriuretic Peptide
bp	Base Pair
CABG	Coronary Artery Bypass Grafting
CAD	Coronary Artery Disease
cAMP	Cyclic Adenosine Monophosphate
CCBs	Calcium Channel Blockers
CD4	Cluster of Differentiation 4
CESI	Carboxylesterase
CI	Confidence Interval
CK	Creatine Kinase
CK-MB	Creatine Kinase (Cardiac isoenzymes)
CK-MB _{1 and 2}	Creatine Kinase isoforms
COX-1	Cyclo-Oxygenase 1
CPIC	Clinical Pharmacogenetics Implementation Consortium
CRP	C-Reactive Protein
CT	Computed tomography
cTn	Cardiac Troponin
cTnI	Cardiac Troponin I
cTnT	Cardiac Troponin T
CVD	Cardiovascular Diseases

CURE	Clopidogrel in Unstable Angina to Prevent Recurrent Events
<i>CYP2C19</i>	Cytochrome P450 2C19
<i>CYP450</i>	Cytochrome P450
<i>DAPT</i>	Dual Antiplatelet Therapy
DC	Dendritic Cells
DM	Diabetes mellitus
DNA	Deoxyribonucleic Acid
dNTP	Deoxyribonucleotide Triphosphate
ECG	Electro-Cardiogram
ED	Emergency Department
EM	Extensive Metabolizers
ER	Endoplasmic Reticulum
ESC	European Society of Cardiology
FAST-MI	French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction
FDA	Food and Drug Administration
GDF-15	Growth Differentiation Factor-15
GoF	Gain of function
GP	Glycoprotein
GRACE score	Global Registry of Acute Coronary Events
GPBB	Glycogen Phosphorylase Isoenzyme in Brain and Heart
GWAS	Genome-Wide Association Studies
H- FABP	Heart Fatty Acid Binding Protein
HF	Heart failure
hs-CRP	High Sensitive C-Reactive Protein
hs-Tn	High Sensitivity Tn
IL	Interleukin
IM	Intermediate Metabolizers
IFN- γ	Interferon-Gamma
IHD	Ischemic Heart Disease
ITGB	Integrin Subunit Beta 3
IV	Intravenous
LD	Loading Dose
LDH	Lactate Dehydrogenase
LDL	Low Density lipoprotein
LMWHs	Low Molecular weight heparin
LOF	Loss-of-Function Allele
LV	Left ventricular
LVEF	Left Ventricular Ejection Fraction
MACE	Major Adverse Cardiac Events
MAF	Minor Allele Frequencies

MDR1	Multi-Drug Resistance 1 Protein
MDRS	MPO-Derived Reactive Species
MI	Myocardial Infarction
MMPs	Matrix Degrading Metalloproteinases
MPI	Myocardial perfusion imaging
MPO	Myeloperoxidase
MS	Metabolic syndrome
NETs	Neutrophil Extracellular Traps
NGS	Next Generation DNA Sequencing
NLRP	Nucleotide-binding domain and Leucine-Rich repeat containing Proteins
NSTEMI	Non-ST Elevation Myocardial Infarction
OPR	On-treatment Platelet Reactivity
OR	Odd Ratio
PAI-1	Plasminogen Activator Inhibitor-1
PAD	Peripheral Artery Disease
PAR	Platelet Protease-Activated Receptor
PCI	Percutaneous Coronary Interventions
PCR	Polymerase Chain Reaction
PD	Pharmacodynamics
PDE-3	Platelet Phosphodiesterase-3
P-GP	Permeability G-protein
PK	Pharmacokinetics
P2Y12	ADP platelets receptor
PLATO	Platelet Inhibition And Patient Outcomes
PM	Poor Metabolizers
PMN	Polymorphonuclear Leukocytes
PO	Per oral
PPIs	Proton Pump Inhibitors
PPi	Pyrophosphate
PTGSI	Prostaglandin G/H synthase I
PTT	Partial Thromboplastin ime
RBG	Random Blood Glucose
SaO ₂	Oxygen Saturation
SC	Subcutaneous
SHH	Sonic hedgehog gene
SNPs	Single Nucleotide Polymorphisms
STEMI	ST Elevation Myocardial Infarction
TAE	Tris/Acetate/EDTA buffer
T2D	Type 2 Diabetes
TGF-β	Transforming Growth Factor-βeta
Th	T helper Lymphocytes

TIMI score	Thrombolysis in Myocardial Infarction
TLR	Toll-Like Receptor
Tn	Troponin
Tn (I, C, T)	Troponin isoforms
TNF	Tumor Necrosis Factor
TP β	Thromboxane Receptor
tPA	Tissue-type Plasminogen Activators
Treg	Regulatory T cells
TRITON-TIMI 38	Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis In Myocardial Infarction ³⁸
TXA ₂	Thromboxane A ₂
UA	Unstable Angina
UFH	Unfractionated Heparin
UM	ultrarapid Metabolizers
uPA	Urokinase-type Plasminogen Activators
VASP	Vasodilator-Stimulated Phosphoprotein
VASP-P	Phosphorylated Vasodilator-Stimulated Phosphoprotein
vWF	von Willebrand Factor
WHO	World Health Organization

Table of Contents

Title	Page No.
List of Tables	vii
List of Figures	viii
Abstract	ix
Introduction	1
Review of Literature	5
Epidemiology of Acute Coronary Syndrome	5
Signs And Symptoms Of Acute Coronary Syndrome (Acs)	6
Causes & Risk Factors Of Acs	7
Pathophysiology of Acute Coronary Syndrome	10
Diagnostic Pathways of ACS	15
Management of ACS	20
Medications Used To Manage ACS	21
Antiplatelet Agents	23
Genes Affecting Dual Antiplatelet Therapy:	36
PEAR1 Polymorphisms	37
CYP2C19 Polymorphisms	38
Aim of the study	44
Patients and Methods	45
1.Study design and population	45
2. Sample collection	47
3.DNA isolation and genotyping	47
Methods	47
A. Automated DNA purification from Blood on the QIAcube (Spin Protocol)	47
B. Evaluating the quality of the extracted DNA	50
C Polymerase Chain Reaction (PCR)	51
D. Genotyping analysis	53

Title	Page No.
Genotyping of <i>CYP2C19</i> *4, <i>CES1</i> P2 Y12	53
Genotyping of PEAR-1 and PON1	58
Statistical Analysis	60
Results	61
- Baseline characteristics of the study population	61
- Studied genes frequencies	63
- P2Y12 polymorphism	68
- <i>CES1</i> polymorphism	70
- PEAR-1 polymorphism	73
- PON1 polymorphism	75
- <i>CYP2C19</i> *4B polymorphism	77
Discussion	79
Summary	96
Limitations	98
Conclusion	99
References	100
Arabic Summary	-

List of Tables

Table (1). Unstable Angina, NSTEMI, and STEMI: How They Differ (Anderson et al., 2007)	9
Table (2): Biochemical markers of cardiac injury (Janota, 2014).....	19
Table (3): Initial Drug Therapy for Acute Coronary Syndrome (Anderson et al., 2007).....	22
Table (4): Adjunctive Drug Therapy for Acute Coronary Syndrome (ACS)* ..	22
Table (5): Reagents used in DNA extraction	48
Table (6): Pyrosequencing PCR and sequencing primers for CES1 583,613, CYP2C19*4B, P2Y12 alleles, at annealing temperature 58°C.....	54
Table (7): The Demographic data, Medical history and concomitant medications of all studied patients population.....	62
Table (8): Comparison between minor allele frequencies of studied genetic polymorphisms in Egyptians compared to other population.....	65
Table (9): Distribution of the studied genetic polymorphisms in MACE and NO-MACE patients.....	66
Table (10): Simple logistic regression association analysis between Major Adverse Cardiac Events (MACE) and genetic and non-genetic factors in Clopidogrel-treated patients.....	67
Table (11): Multiple logistic regression analysis showing genetic and non-genetic factors significantly associated with Major Adverse Cardiac Events in Clopidogrel-treated participants.....	68

List of Figure

Figure (1): Diagrammatic illustration of Acute Coronary syndrome pathogenesis (<i>Fuster et al., 1992</i>).....	15
Figure (2): Schematic diagram of ECG for normal heart versus STEMI and NSTEMI (<i>Hasdai et al., 2002</i>).....	18
Figure (3): Cardiac markers following ACS event (<i>French and White, 2004</i>).....	19
Figure (4): Factors affecting platelet activation and aggregation (<i>Giusti et al., 2014</i>)...24	24
Figure (5): Diagrammatic illustrations of various types of antiplatelet drugs (<i>Kasthuri et al., 2010</i>).....	25
Figure (6): Diagrammatic illustration of the two groups included in the current study.....	46
Figure (7): Bar chart showing the distribution of the P2Y12 genotyping variants among the studied groups.....	68
Figure (8): Pie-chart representing the P2Y12 polymorphisms in the participants.....	69
Figure (9) P2Y12 1000 Genomes allele Frequency among various populations.....	69
Figure. (10): Pie-chart representing CES1 (rs3815583) polymorphisms.....	70
Figure (11): Comparison of CES1 (rs3815583) genotypic variants between studied groups: NO significant difference between cases and controls are revealed, P-Value of CES1. rs3815583: 0.65.....	71
Figure (12): CES1 (583) 1000 Genome allele Frequency among various populations....	71
Figure (13): Pie-chart representing the CES1(rs2244613) polymorphism.....	72
Figure (14): Comparison of the CES1 (rs 613) genotypic variants between 2 studied groups.	72
Figure (15): Pie-chart representing the PEAR1polymorphisms.....	73
Figure (16): Comparison of PEAR-1 genotypic variants between the two studied groups.....	74
Figure (17): Plot showing allelic discrimination and genotyping of PEAR-1 using TaqMan technique.....	74
Figure (18): Pie chart showing PEAR-1 1000 Genome allele frequency among various populations.....	75
Figure (19): Pie chart representing PON1 polymorphisms.....	76
Figure (20): Plot showing allelic discrimination and genotyping of PON-1 using TaqMan technique.....	76
Figure (21): Bar chart showing PON1polymorphism.....	77
Figure (22): Pie chart presenting CYP2C19*4B 1000 Genome allele Frequency.....	77
Figure (23): Bar chart showing that the comparison of CYP2C19*2 between the two groups.....	78

ABSTRACT

Dual antiplatelet therapy (DAPT) with aspirin and Clopidogrel reduces the risk for recurrent cardiovascular events after acute coronary syndrome (ACS) and percutaneous coronary intervention. However, there is significant variation in response to DAPT that may be influenced by both genetic and non-genetic factors. The aim of the present study was to assess the effect of genetic polymorphisms in *PON1*, *PEAR-1*, *P2Y12*, *CES1* and *CYP2C19* along with clinical, demographic, and social factors, on variation in response to Clopidogrel plus aspirin therapy in Egyptians. This study included 230 Egyptian patients treated with Clopidogrel 75 mg/day and aspirin 81 mg/day for at least 12 months following their first ACS. It was found that *CYP2C19**2 polymorphism was the only genetic predictor of major adverse cardiovascular events (MACE), defined as the occurrence of recurrent ACS, ischemic stroke, stent-related revascularization or death (OR 2.23, 95% CI: 1.15 – 4.33, p=0.01). Moreover, the use of proton pump inhibitor (PPI) (OR 4.77, 95% CI: 1.47 – 15.54, p=0.009) and diabetes (OR 1.83, 95% CI: 1.03 – 3.26, p=0.03) were associated with higher cardiovascular risk, while the use of statins was associated with lower risk (OR 0.43, 95% CI: 0.25 – 0.76, p=0.003). The contribution of these five genetic and non-genetic factors explained 19% of the variability in risk for MACE in Egyptians treated with Clopidogrel and aspirin. The previously mentioned results showed that *CYP2C19**2 polymorphism, along with diabetes, and use of PPI and statins are important factors highly associated with the variability in clinical response to Clopidogrel plus aspirin following ACS in Egyptians.

Keywords: Clopidogrel, aspirin, dual antiplatelet, Egyptians, P2RY12, CES1, CYP2C19.

INTRODUCTION

Acute coronary syndrome (ACS), a form of coronary heart disease, has a substantial economic and societal impact in various countries. Epidemiological data showed that re-infarction and death are the two major clinical outcomes following ACS. It was established that people 40 years old or more (*18% of males and 23% of females*) may suffer from death after 1 year of myocardial infarction MI (*Lloyd et al., 2011*). Information concerning the demographics in Egyptian patient with ACS is incompletely clear.

Platelet attachment, activation, and aggregation after plaque rupture or abrasion are significant determinants of blood vessel thrombosis prompting ACS. Antiplatelet treatment, which targets pathways of platelet activation and aggregation, is essential in the treatment of ischemic occasions in ACS patients. Pharmacotherapy for ACS includes anticoagulants, fibrinolytics, and antiplatelet drugs to diminish the rate of cardiovascular events (*Kushner et al., 2009*).

Dual antiplatelet therapy (DAPT) as Clopidogrel, prasugrel or ticagrelor in conjunction with aspirin, is the treatment of choice in ACS patients. Drug choice should be based on the individual patient's characteristics and contraindications; Clopidogrel will be used if, prasugrel and ticagrelor are contraindicated or not obtainable. There is a strong evidence that DAPT with aspirin and thienopyridines (e.g. Clopidogrel), can significantly reduce the cardiovascular events in patients with all types of ACS (*Anderson et al., 2007*), with or without percutaneous coronary intervention. On the basis of this evidence, antiplatelet therapies are generally accepted as the standard of care for the management of ACS (*Kushner et al., 2009*).

It is recognized that atherothrombosis is the most widely recognized cause behind ACS, and has a pivotal role in developing

complications. Vascular endothelial damage and plaque burst are events prompted for platelet adhesion, and aggregation causing thrombosis, ischemia, and infarction that is the main pathology of ACS. Inhibition of platelet aggregation (IPA) by pharmacological treatment prevents formation and progression of thrombotic processes (*Jennings, 2009*).

Aspirin or DAPT with aspirin and Clopidogrel, a thienopyridine, has been considered as the cornerstone of antiplatelet therapy in an attempt to prevent complications among patients with ACS (*Scott et al., 2013, Levine et al., 2014*). Around 85% of Clopidogrel is hydrolyzed in the liver during the first-pass metabolism by esterase, essentially carboxylesterase 1 (CES1), to inactive metabolites. the remaining 15% of Clopidogrel prodrug will be converted to an active metabolite that happens in the liver by two consecutive oxidation steps that include several cytochrome P450 (CYP450) enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4/5) (*Scott et al., 2013*).

An association between *CYP2C19* gene polymorphisms and the enzyme activity has been demonstrated. The most common genetic variation, designated as *CYP2C19*2*, leads to a splicing defect that functionally affects the enzyme resulting in loss of function. The *CYP2C19*2* allelic variant has been associated with higher levels of ADP-induced platelet aggregation values in Clopidogrel-treated patients and, consequently, a higher risk of adverse cardiovascular events, as stent thrombosis (*Collet et al., 2009*). Moreover, an allelic variant recently reported, *CYP2C19*17* has been associated with increased enzyme function (*Simon et al., 2009*). Thus, individuals harboring this genetic variant could have an enhanced response to antiplatelet treatment with Clopidogrel, improving the prevention of thrombotic events, but, on the other hand, having a putative increased risk of bleeding (*Sibbing et al., 2011*).

In humans, carboxylesterase **CES1** is the most predominant hydrolytic enzyme, catalyzing the hydrolysis of numerous ester- and